Related by context. All words. (Click for frequent words.) 64 efficacy evaluable 62 Binding Letter 59 Non Binding Letter 58 Terminates Letter 57 signed Binding Letter 56 Last Observation Carried 56 Executes Letter 55 prospectively defined 53 Exelixis XL# 53 Signs Binding Letter 53 Statistically Significant 50 Dose Escalation 50 Stuart Dinsey 50 Phase 2b Study 50 ANCOVA 50 Progenitor Cells 49 Randomized Evaluation 49 Rheumatoid Arthritis Patients 49 RECIST Response Evaluation Criteria 49 JAK Inhibitor 49 Main Outcome Measures 49 CORE OM 49 Prognostic Value 48 secondary efficacy endpoint 48 Lung Cancer Trial 48 Relapsing Remitting Multiple Sclerosis 48 Solid Tumors criteria 48 Pivotal Trials 48 Permitted Uses 48 binding Letter 48 Bloodstream Infections 48 Brain Metastases 48 Localized Prostate Cancer 47 Prognostic 47 Thrombus 47 Secondary efficacy endpoints 47 florbetaben 47 Diamyd Medical Diamyd 47 HF ACTION 47 Hormonal Therapy 47 Randomized Clinical Trials 47 Deliver Cocaine 47 Novel Therapeutic 47 Neoadjuvant Chemotherapy 47 Delist Common Stock 47 Letter 47 Investigational Agent 47 Universal Flu Vaccine 47 Confirmatory Phase 47 Lymph Nodes 47 Solid Tumors 47 Metastatic Renal Cell Carcinoma 47 STRIDE PD 47 Treating Chronic 47 undergoing coronary angiography 46 etiologic 46 Pharmacokinetic PK 46 FDG-PET/CT 46 Fracture Risk 46 Stockholder Approval 46 Tumor Cells 46 Radiation Induced 46 Express Warranties 46 Ischemic 46 Urgent Intervention Triage 46 Stable Angina 46 differential gene expression 46 Tumor Response 46 Viral Suppression 46 Gastrointestinal Stromal Tumors 46 Inflammatory Pain 46 Predict Prostate Cancer 46 Genetic Variation 46 Pralatrexate 46 Sociodemographic 46 #F FDG PET 46 Primary endpoints 46 Quantifiable 46 Subgroup Analysis 45 Predictive Value 45 HRQL 45 Main Outcome Measure 45 Randomized Study 45 Angiogenic 45 Randomized Controlled Trials 45 Clinical Outcome 45 HCV SPRINT 45 observational cohort study 45 Breast Density 45 Potent Inhibitor 45 tipranavir ritonavir 45 Non Responders 45 Detect Cancer 45 Significant Efficacy 45 Bone Marrow Cells 45 covariate 45 Ineffective Assistance 45 Treat Heart Failure 45 Distribute Marijuana 45 Carotid Stenting 45 Greystar Resources Announces 45 Medication Adherence 45 RECIST criteria 45 Hematological Cancers 45 Summary Judgment Motions 45 Solid Tumours 45 Subtypes 45 clinically meaningful improvement 45 mean ± SEM 45 Cardiogenic Shock 45 Genetic Mutation 45 EQ 5D 44 Multicenter Phase 44 TB Vaccine 44 Combination Clinical Trial 44 Primary Endpoint 44 Interferon Alfa 44 Herpes Virus 44 Depressive Symptoms 44 Nicotine Vaccine 44 Data Suggest 44 Binding Agreement 44 interobserver 44 Effective Treatments 44 Peripheral Blood 44 Bioavailability 44 Prolongation 44 meta regression 44 Mammographic 44 Sexual Satisfaction 44 CHMP Opinion 44 Cardiac Function 44 TIMP 1 44 Prospective Randomized 44 Multicenter Trial 44 Gene Mutation 44 Genes Linked 44 Blocked Arteries 44 Efficacious 44 multivariate analyzes 44 logistic regression model 44 bortezomib refractory 44 Radiofrequency Ablation 44 Septic Shock 44 Heterogeneity 44 Protein Linked 44 Diagnostic Criteria 44 Genotype 44 retrospective observational study 44 Deliver Controlled Substance 44 Inhaled Corticosteroids 44 Vasculature 44 Genetic Variants 44 attain statistical significance 44 Psychodynamic Psychotherapy 43 Protein Interactions 43 Treating Depression 43 Antipsychotic Drug 43 FDA Issues Approvable 43 Restated Letter 43 Watchful Waiting 43 Cardiovascular Outcomes 43 Predominant 43 Coronary Arteries 43 Enters Into Letter 43 impunity admonitory 43 viral kinetics 43 Epithelial Cell 43 clinico pathological 43 retrospective cohort 43 No Observed Adverse 43 Pluripotent Stem Cells 43 Childhood Immunizations 43 Myocardial Ischemia 43 Maximum Tolerated Dose MTD 43 Sustained Efficacy 43 Cholinesterase Inhibitors 43 Share Issuance 43 Randomized phase 43 prospective longitudinal 43 Annexures 43 Dose Reduction 43 Montgomery Åsberg Depression 43 Regulatory Clearance 43 -#:# GMT/# 43 Modifiable 43 Mutagenesis 43 Unmet Medical 43 Proposed Rule Changes 43 Univariate analysis 43 Prostate Cancer Risk 43 Lung Function 43 Randomised 43 NICE SUGAR 43 Prolongs Life 43 Selectivity 43 bivariate analyzes 43 Genetic Markers 43 Left Ventricular 43 PLCO 43 logistic regressions 43 Targeted Therapy 43 Antidepressant Treatment 43 chest radiographs 43 Cognitive Function 42 Comorbidities 42 Repeatability 42 Lesion 42 Structural Changes 42 psychiatric morbidity 42 Selection Criteria 42 Left Atrial 42 Demonstrated Significant 42 Rating Scale BPRS 42 Homeostasis 42 logistic regression analyzes 42 Specificity 42 Cardiopulmonary bypass 42 Supplementary Table 42 psychiatric outpatients 42 Vitamin D Supplementation 42 Epileptic Seizures 42 Consensus Statement 42 Sirolimus Eluting Stent 42 Menstrual Pain 42 Airborne Geophysical 42 Protein Structures 42 sociodemographic characteristics 42 baseline FEV 42 NIH CPSI 42 Receives Complete Response 42 Surgical Procedures 42 Cardiorespiratory fitness 42 fluorodeoxyglucose positron emission tomography 42 Preliminary Consent Revocation 42 SF #v# 42 demographic variables 42 Content Outline 42 limiting generalizability 42 Personality Questionnaire 42 Proxy Proposals 42 Brain Scans 42 Embryonic Stem Cells 42 Lung Tumor 42 OBJECTIVES 42 Vertebral Fractures 42 Tumor Cell 42 Key Findings 42 pharmacodynamic effects 42 IntroductionThe 42 prospective multicentre 42 polyarticular 42 Microdosing 42 EBMT criteria 42 Potential Delisting 42 plasma pharmacokinetics 42 Intervention Trial 42 Opioid Use 42 Sleep Disturbance 42 Secondary endpoints 42 Treatment Outcome 42 Waiver Agreement 42 Revised Proposal 42 NASDAQ Delisting 42 Innate Immune 42 Shareholder Meeting Date 41 pharmacodynamic PD 41 Sufficient Evidence 41 Rate Climbs 41 subanalysis 41 Secondary endpoints include 41 Outcome Measures 41 Ordinary Dividends 41 CSBM 41 Psychosomatic Research 41 Alkaline Phosphatase 41 bivariate 41 Harsh Tactics 41 APOE genotype 41 Tumor Suppressor Gene 41 Lorus Therapeutics Announces 41 Breast Tissue 41 Protein Synthesis 41 -Patney 41 convergent validity 41 Brief Psychiatric 41 Patient Populations 41 Length Au 41 Antibiotic Treatment 41 Broadened 41 Histopathologic 41 Harsh Interrogation 41 FOR AN OPEN 41 STRATEGY FOR AN OPEN 41 Treatment Diabetic Retinopathy 41 prospective observational cohort 41 Resale Registration Statement 41 Genetic Marker 41 Randomized controlled 41 Vertebral Fracture 41 Length Width 41 Smooth Muscle 41 FACIT 41 Clinical Relevance 41 Various Types 41 Gender Differences 41 PDL BioPharma Announces 41 Abciximab 41 Wrong Message 41 Placebo Effect 41 Androgen Deprivation 41 Malaria Vaccine 41 Postmenopausal Hormone Therapy 41 Peer Reviewed Publication 41 Evaluative 41 Phenotypes 41 SSAO 41 Comprehension 41 LibiGel NDA 41 TIMP 41 Solutia disclaims any 41 Screening Tool 41 Severity Index PASI 41 BALF 41 International Prostate Symptom 41 Impairs 41 FDG PET scans 41 Phenotypic 41 Analytical Method 41 MDRD 41 Eye Diseases 40 Study Evaluates 40 NexMed Receives 40 Enhance Shareholder 40 Descriptive statistics 40 Platelet Aggregation 40 Estrogen Therapy 40 Novel Approach 40 BiTE Antibody 40 somatization disorder 40 GISSI 40 Distribute Methamphetamine 40 Study Shows Benefits 40 Morphological 40 STEP BD 40 Risk Stratification 40 guideline concordant 40 Unlock Secrets 40 Stockholder Vote 40 Pharmacogenomic 40 Myocardial 40 depression suicidality 40 Cautionary Factors 40 Self Efficacy 40 Previously Disclosed 40 DLQI 40 Ischaemic 40 NHANES III 40 Distinctiveness 40 Action Lawsuit 40 NAMCS 40 Visual Analogue Scale VAS 40 psychometric properties 40 Erythropoietic 40 Myocardial Infarction 40 Proportionality 40 Registration Statement Relating 40 Wisconsin Sleep Cohort 40 EUROCARE 40 Powerful Tool 40 Results Indicate 40 POIS 40 Key Milestones 40 AQUARIUS PLATINUM LIMITED 40 Pricing Supplement 40 HRQOL 40 Tumor Targeted 40 Outcomes Study 40 Normative 40 Showed Significant 40 Conditional Approval 40 Regression Analysis 40 Socio demographic 40 logistic regression models 40 HADS 40 NASDAQ Deficiency Notice 40 Prejudiced 40 Patellofemoral 40 Renal Tumors 40 Their Respective 40 Notice 40 Iron Deficiency Anemia 40 subscale scores 40 EORTC QLQ C# 40 Shareholder Letter 40 Therapeutic Antibody 40 Secondary endpoints included 40 Regain Compliance 40 Neuropsychiatric Inventory NPI 40 Artificial Cornea 40 longitudinal cohort study 40 chlamydial infection 40 Extrinsic 40 Chronic Pelvic Pain 40 Cell Adhesion 40 Microfluidic Devices 40 Shareholder Approval 40 dietary questionnaires 40 Defendant Motion 40 Charlson Comorbidity Index 40 Nasdaq Deficiency Notice 40 Cognitive Problems 40 DEFER 40 Mukasey Nomination 40 Pacific Rubiales Announces 39 Complementarity 39 Epitopes 39 Pressure Monitoring 39 Predict Dementia 39 pain subscale 39 telomere lengths 39 Improving Outcomes 39 Anthera disclaims 39 Signaling Pathways 39 Relieve Depression 39 Skin Cells 39 Verenium expressly disclaims 39 posttest 39 Recurrence Risk 39 schizophrenia schizoaffective disorder 39 Arbitration Proceedings 39 Nutrition EPIC 39 Skin sterol 39 Echocardiographic 39 Alexco Announces 39 Questionnaire 39 interrater reliability 39 multicentre randomized 39 Increase Conversions 39 CARDIA 39 Personality Traits 39 Insufficiency 39 Change PGIC 39 Diabetic Retinopathy 39 Receives FDA Approvable 39 Conclusions 39 Etiology 39 multicenter randomized controlled 39 Medoro Resources Announces 39 multiple logistic regression 39 Sotomayor Nomination 39 METHODS 39 ANOVA 39 Prospective Multicenter 39 Second Tranche 39 Inflammatory Response 39 ECLS 39 healthy unmedicated 39 Genes Involved 39 Study Explores 39 Arterial Hypertension 39 erection hardness 39 Theratechnologies Announces 39 DEXA scan 39 Systolic Blood Pressure 39 Glucose Monitoring 39 Meta Analyses 39 Nerve Cell 39 Complicated Grief 39 Lower Limb 39 anthropometric measurements 39 core needle biopsies 39 subscores 39 neuropsychological assessment 39 Pneumonia Vaccine 39 Community Acquired Pneumonia 39 Angiographic 39 Mutational 39 Appendix VII 39 Strongly Linked 39 bivariate analysis 39 Interval m 39 Hotly Debated 39 Unsolicited Proposal 39 Temporary Suspension 39 dimensional echocardiography 39 Clinical Significance 39 Ramco Gershenson Announces 39 Exercise Notices 39 Ethnic Differences 39 Inequitable Conduct 38 Distress Scale 38 Lifestyle Intervention 38 Reduce Expenses 38 Mathematical Model 38 annexed hereto 38 theAmerican Journal 38 Cognitive Deficits 38 -Living Independently 38 #F FDG PET CT 38 sociodemographics 38 Artificial Pancreas 38 Knee Replacements 38 Letters 38 Imaging Techniques 38 Multicenter AIDS 38 Fibrinogen 38 ATW Transaction 38 Adverse Outcomes 38 Generalized 38 Determinant 38 Mamadou Dem 38 Consumer Preferences 38 Hematopoietic Stem Cell 38 Computed 38 Index FSFI 38 Acquisition Proposal 38 PANSS Positive 38 Cervical Spine 38 Nasdaq Delisting Notification 38 MCID 38 Remission Maintenance 38 Prostate Cancer Diagnosis 38 Cystic Fibrosis Questionnaire Revised 38 activating mutation 38 Deficiency Letter 38 randomisation 38 Adversely Affect 38 noncognitive 38 Reproducibility 38 Repl. 38 Lung Cancer Vaccine 38 Secret Detentions 38 UroToday.com Contributing Medical 38 Synthesize 38 Defendants Motion 38 Usefulness 38 Purported Class 38 Defendants Motions 38 RFEI 38 DAS# scores 38 Ocular Surface Disease 38 Diminishes 38 Functional Assessment 38 Survey MEPS 38 FAR Clause #.#-# 38 Continued Listing Requirements 38 Spatio Temporal 38 Sleep Duration 38 Reincorporation 38 Mechanistic 38 Quantification 38 Assessed Value 38 adjuvant endocrine therapy 38 randomized controlled trials RCTs 38 Threatening Letters 38 Prostate Cancer Cells 38 NASDAQ Listing Requirements 38 Annexin 38 QoL 38 covariates 38 Likert Scale 38 Early Diagnosis 38 Occluded 38 Stmt 38 Molecular Mechanism 38 Collaborative Approach 38 Reperfusion 38 Logistic Regression 38 Be Avoided 38 retrospective cohort study 38 Statement 38 Psychodynamic 38 Preferred Stock Dividend 38 Voluntarily Delist 38 Osteoarthritis Pain 38 5 HTT gene 38 Capitalist Nigger 38 Female Sexual Function 38 Conclusion 38 Anthropometric 38 Tumor Suppressor 38 Conditions Precedent 38 Depression Inventory 38 liver biopsies 38 Determination 38 SPIVA methodology 38 Chronic Illness Therapy 38 Position Statement 38 multivariate logistic regression 38 Antibiotic Resistant Bacteria 38 Proposed Reorganization 38 TOP ARTICLE 37 Listing Compliance 37 C.# 37 Waiver Request 37 Glycosylation 37 Exelbine NDA 37 semiquantitative 37 Correlation Between 37 Amended Judgment 37 Cu Equivalent 37 eNO 37 Hindrances 37 Surface Temperature 37 PANSS 37 LUX Lung 37 Delayed Filing 37 Genuine Occupational 37 PSQI 37 multicenter phase 37 First BanCorp Announces 37 prospective cohort 37 Opting Out 37 EPDS 37 Ark. Sup 37 Multivariate analyzes 37 RE MODEL 37 Quotation RFQ 37 Demonstrates Ability 37 MDQ 37 Commence Tender Offer 37 logistic regression 37 doi doi 37 Provides Clarification 37 Gentex Declares Quarterly 37 xsl template 37 Carried Interest 37 Retraction 37 Injury Severity 37 Genetic Defect 37 Regains NASDAQ 37 Unimin Offer 37 Zcom Networks Announces 37 -India Kanishka bombing 37 Mineable 37 Substantial Issuer Bid 37 Consultation Document 37 Verbal Reasoning 37 Overviews 37 Cost Effectiveness 37 Same Sex Unions 37 Initiated Phase 37 Framingham Offspring 37 Comparative Effectiveness 37 Objective 37 Exclusivity Period 37 dkt 37 Visual Analog 37 Personality Disorder 37 Cronbach alpha 37 Trajectories 37 Anxiety Depression 37 Listing Requirement 37 Visual Analogue Scale 37 Homogeneity 37 JAAPA 37 QIDS SR 37 Reply Brief 37 Mandatory Redemption 37 Human Embryo 37 Subscale 37 Merger Proposal 37 Same Sex Marriage Licenses 37 Handedness 37 Religious Belief 37 37 morphologic characteristics 37 Obtains Financing 37 Bird Flu Outbreaks 37 Quantified 37 Correlate 37 Appraised Value 37 Arbitration Agreements 37 Issuer Amended 37 Polyunsaturated Fatty Acids 37 PREFERRED QUALIFICATIONS 37 Redetermination 37 Shortfall Application Form 37 doi #.#/j.#-#.#.#.x 37 Sustained virologic response 37 Confidentiality Agreements 37 Randomized Placebo Controlled Trial 37 Cluster Headaches 37 Lives Remembered 37 Multivariate analysis 37 lifetime abstainers 36 MINDSET 36 Supplemental Figure 36 Microenvironment 36 Critical Elements 36 PQQ 36 Invariant 36 Guideline 36 Muscarinic 36 Often Overlooked 36 Periodic Reports 36 somatization 36 periodically reassessed 36 Protein Structure 36 Submits Letter 36 Optionholder 36 Continued Listing 36 Correlated 36 NCDB 36 Racial Diversity 36 Clin Trials 36 Regain Compliance With 36 Minimum Stockholders Equity 36 Investigator Initiated 36 NHAMCS 36 RADIANT 36 Regular Monthly Distributions 36 Intent contemplates 36 Misperception 36 Pain Rating Scale 36 Dividend Payments 36 Synaptic Plasticity 36 Better Outcomes 36 Recapitalization Plan 36 Systematic Approach 36 Unsolicited Offer 36 Previously Announced Tender Offer 36 Improving Profitability 36 Receives Unsolicited 36 ‰ ¥ 36 Regulatory Filing 36 Term Sheet 36 Superiority 36 SCENIHR 36 Acute Physiology 36 Achieve Success 36 State Trait Anxiety 36 Gives Clues 36 Propensity 36 Grandfathered Plans 36 Wechsler Adult 36 virginity pledgers 36 Supplemental Circular 36 Federal eRulemaking Portal http:/www.regulations.Tavarekere 36 Likert scale 36 Remain Listed 36 Health Assessment Questionnaire 36 antidepressant therapy 36 Linearity 36 Therapeutic Intervention 36 License Application 36 Proposed Arrangement 36 Difficulties Questionnaire 36 Materiality 36 Depression Inventory BDI 36 Debt Tender Offer 36 FOIA Requests 36 PennyStockBets.com employees 36 Recall Petition 36 Explanatory Notes 36 Drilling Permit 36 Swedish Mammography Cohort 36 Individual Differences 36 Reading Fluency 36 Plaintiff Motion 36 Shareholder Applicants 36 EXECUTIVE SUMMARY 36 attached herewith 36 Thus AEGY disclaims 36 CPMP 36 Statement EIS 36 Bonferroni correction 36 Not Guilty Pleas 36 Shelf Registration Statement 36 Critical Success Factors 36 Characterize 36 Empower Yourself 36 Quantify 36 Improve Quality 36 Joint Stipulation 36 OCGA § #-#-# [002] 36 Estoppel 36 Shareholder Proposals 36 urbanicity 36 Proposed Private Placement 36 enzyme immunoassay EIA 36 National Epidemiologic Survey 36 NASDAQ Listing Qualification 36 Solicitation Number 36 Successful Implementation 36 preservice teachers 36 Evaluation Process 36 Quotations RFQ 36 Cognitive Ability 36 What Constitutes 36 Folic Acid Fortification 36 Novel Technique 36 socio demographic 36 Unintended Consequence 36 Supplementary Prospectus 36 Macroscopic 36 Pearson correlation coefficients 36 Alito Nomination 36 Directors Shareholdings 36 Amended Notice 36 Restated Promissory Note 36 Submittals 36 DSM IV diagnoses 36 Reevaluation 36 Considered Resigning 36 Restatement Process 36 Wyo. Stat 36 § #.# Vernon 36 Constrain 36 OBJECTIVE 36 Knee Jerk 36 Neuropsychological Status 36 BPRS 35 pelvic ultrasound 35 Unsolicited Acquisition 35 Urigen URG# 35 Deregister 35 Order Granting 35 Unsolicited Proposal From 35 Minimize Risk 35 Platelet Function 35 Classify 35 multicentre study 35 Statewide Smoking Ban 35 enclosed herewith 35 journal Urology 35 endometrial biopsy 35 nonfasting 35 EFFECTIVE DATE 35 Order Authorizing 35 Due Diligence Period 35 avoidant personality disorder 35 Figure S4 35 Global Impression CGI 35 Memorandum Opinion 35 Detection Device 35 Measurement Uncertainty 35 Visual Analog Scale 35 Efficacy endpoints 35 Restricts Access 35 Lancet Neurology journal 35 Political Ideology 35 Paul Haggis Letters 35 Filing Status 35 Option Grants 35 Receives Notification 35 Descriptive 35 Pooling Agreement 35 Anti Malarial 35 QTL mapping 35 Geriatric Depression 35 Segmental 35 PhD Thesis 35 Jeanne Eagels 35 waist circumference WC 35 parties hereto 35 Redemption Notice 35 Timeframe 35 A.2 35 Aortic Dissection 35 C.1 35 Methods 35 Catenin 35 CO2 Emission 35 Threatening Letter 35 EoE 35 Comprehensive Approach 35 Molecular Structure 35 Child Mortality 35 Patient Satisfaction Survey 35 Cardiopulmonary Bypass 35 Methodological 35 Molecular Mechanisms 35 Pharmacology Biochemistry 35 Neuropsychologia 35 Mini Tender Offer 35 Regress 35 More Harm Than 35 Res.# 35 Structure Function 35 Mitochondrial Dysfunction 35 Preliminary Proxy Statement 35 Has Been Filed 35 demographic characteristics 35 LoI 35 gender ethnicity 35 Mails Letter 35 Op Ed Contributors 35 Primary Mortgage Servicer 35 subsamples 35 dyads 35 Subsection b 35 MR spectroscopy 35 fasting lipid 35 CARDIA study 35 Rationalize 35 Wholly Owned Subsidiaries 35 Assignment Desk Daybook 35 Offerors Commercial 35 FY# Guidance 35 Accelrys disclaims 35 Microstructural 35 Nasdaq Delisting 35 Clarification Regarding 35 Stimmrechtsmitteilung pursuant 35 Docket Entry 35 Docket Entry No. 35 .W. McNichols 35 Dialectical 35 Pre Emptive 35 Repurchase Offer 35 Thermodynamic 35 Myocardial Perfusion 35 Curriculum vitae 35 Material Fact 35 deCODE BreastCancer TM 35 Shelf Prospectus 35 strongest predictors 35 Amending Agreement 35 NexgenRx Announces 35 Impediment 35 WebTech Wireless Announces 35 CSAMT MT 35 Stipulation 35 Signs Letter 35 Cautionary Announcement 35 Suppressive 35 Minimization 35 preimplantation 35 Symbol Change 35 Compliance Statement 35 sociodemographic 35 genital arousal 35 Self Destructive 35 Proposed Settlement 35 Enhanced Interrogation 35 Amalgamation Resolution 35 3rd edn 35 HRQoL 35 Doc. # 35 Treatment Outcomes 35 Major Step Toward 35 Opinion Piece 35 CJASN 35 Incontinence Impact Questionnaire 35 BRFSS 35 Cashflow Report 34 trimester ultrasound 34 journal Pharmacology Biochemistry 34 Success Depends 34 Receives Notice 34 Receives NASDAQ 34 Conflict Tactics 34 MVEIRB 34 GDPI 34 Partial Offer 34 Remain Divided 34 Vigorously Defend 34 Predestination 34 psychodynamic psychotherapy 34 Remediate 34 Important Message 34 BRCA testing 34 Inverse Distance 34 multiple linear regression 34 Group ObjectBuilders ObjectFocus 34 Favorable Ruling 34 Waste Discharge 34 Mandatory Conversion 34 Directors Circular dated 34 Risk Warning 34 Cognitive Behavioural Therapy 34 opinion@dailycardinal.com 34 multivariate analysis 34 Listing Deficiency 34 Gonzales Resignation 34 Military Recruiters 34 Attainment 34 Competitive Advantages 34 § #-#.# [001] 34 Stereotype Threat 34 Compulsory Acquisition 34 Material Facts 34 SRBI 34 tumor hypoxia 34 Partial Redemption 34 Randomized Trial 34 Kebba Camara 34 Stipulated 34 Exposure Draft 34 Lose Sight 34 Statement FEIS 34 Voluntary Delisting 34 NOBO List 34 Subjective 34 Ascertain 34 Amended Motion 34 Improve Profitability